Study Demonstrates That Avita Medical’s ReCell® Spray-On Skin™ in Combination with a Biological Wound Dressing Has “a Number of Benefits Compared to Standard Skin-Grafting Techniques”

NORTHRIDGE, Calif. & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Avita Medical Ltd. (ASX: AVH), the regenerative medicine company, announced today that a pilot clinical study of 4 patients suffering from deep dermal flame burns to their legs “healed quickly” following treatment with ReCell® Spray-On Skin™ from Avita Medical in combination with a biological dressing “and were able to return to work and activities of daily living with relative ease.”

“and were able to return to work and activities of daily living with relative ease.”

Results of the study (“Biobrane® and ReCell® for the Treatment of Deep Dermal Burns to the Leg—A Comparative Pilot Study”) were presented last month at the 44th annual meeting of the British Burns Association by principal investigator Jeremy M. Rawlins, M.D., Ph.D., Yorkshire Regional Burn Centre & Department of Plastic Surgery, Pinderfields Hospital, Wakefield, United Kingdom.

“This comparative pilot study using ReCell and a biological wound dressing in combination has shown a number of benefits compared to standard skin grafting techniques,” said Dr. Rawlins. “In the ReCell and biological dressing group early, surgical intervention allowed better dermal salvage with the use of the cell based therapy and biological dressing. These techniques result in less pain for the patient, a smaller donor site, faster wound healing and better scar outcomes.”

“Numerous clinical studies have established that our ReCell Spray-On Skin regenerative technology, designed to harness the body’s ability to heal itself, provides significant benefits to the patient, surgeon and health care system. These clinical data are fuelling sales of ReCell as an easy-to-use bedside kit for clinicians in Australia, France, Germany, Portugal, Russia, The Netherlands and the United Kingdom,” said William Dolphin, Ph.D., CEO of Avita Medical.

More than 3,500 patients have been treated with ReCell for treatment of burns, hypo- and hyper-pigmentation (e.g., Vitiligo, a common skin pigmentation disease), scar revisions (e.g., acne), and aesthetic skin rejuvenation procedures (e.g., wrinkle removal). Use of ReCell has been clinically demonstrated to improve outcomes, reduce morbidity, and reduce length of hospital stay and patient care costs.

ABOUT RECELL® SPRAY-ON SKIN™

ReCell allows in‐theatre preparation of a spray‐on suspension consisting of cells derived from a small (2 by 2cm), thin (0.15‐0.20mm) biopsy of the patient’s own skin that is sufficient to cover an area up to 80 times the size of the biopsy. The ReCell suspension contains basal keratinocytes, melanocytes, fibroblasts and Langerhans cells. The metabolically responsive epithelial cells migrate across the wound surface, leading to regeneration of skin of normal color and texture. ReCell requires only a minimal donor site and is immediate available as a cell‐based spray at the patient’s bedside.

ReCell^® is patented, CE marked for Europe, TGA registered in Australia, and SFDA cleared in China. ReCell^® is not available for sale in the United States; in the U.S. ReCell^® is an investigational device limited by federal law to investigational use.

ABOUT AVITA MEDICAL LTD.

Avita Medical (www.avitamedical.com) is a publicly listed medical technology company that develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Using patented and proprietary tissue-culture, collection and application technology, the company is able to provide innovative treatment solutions derived from a patient’s own skin. The company’s lead product, ReCell^®Spray-On Skin, has been designed for use in a wide variety of burns, plastic, reconstructive and cosmetic procedures.

This presentation may include forward-looking statements that involve risks and uncertainties. You can identify these statements by the use of words such as “anticipate”, “estimate”, “expect”, “project”, “potential”, “intend”, “plan”, “believe”, “target”, “may”, “assume” or similar expressions. These forward-looking statements speak only as at the date of this release and are based on management’s expectations and beliefs concerning future events. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of Avita Medical that could cause actual results to differ materially from such statements. Avita Medical makes no undertaking to subsequently update or revise the forward-looking statements made in this release to reflect events or circumstances after the date of this release. This document is intended to provide background information only and does not purport to make any recommendation upon which you may reasonably rely without taking further and more specific advice.